Chemical Namerolapitant
Dosage FormTablet (oral; 90 mg); injection (intravenous; 166.5 mg/92.5 mL)
Drug ClassReceptor antagonists
CompanyTesaro Inc
Approval Year2015


  • Indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Varubi (rolapitant) Prescribing Information2018TerSera Therapeutics LLC, Lake Forest, IL